NCT06271837

A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors

A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) as Monotherapy or in Combination With Anti-cancer Agents for the Treatment of Patients With Selected HER2-expressing Tumors (DESTINY PanTumor03)

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 175 (estimated)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 18 Years – 130 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label, multicenter, Phase II study to evaluate the efficacy and safety of trastuzumab deruxtecan as monotherapy or in combination with anti-cancer agents for the treatment in locally advanced, unresectable, or metastatic patients with selected HER2-expressing solid tumors which are not eligible for curative therapy.

Conditions

• Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)

Interventions

Type	Name	Description
DRUG	Trastuzumab deruxtecan	Trastuzumab deruxtecan by intravenous infusion
DRUG	Bevacizumab	Bevacizumab by intravenous infusion

Timeline

• Start date: 2024-02-18
• Primary completion: 2025-10-30
• Completion: 2027-04-01
• First posted: 2024-02-22
• Last updated: 2025-10-22

Locations

31 sites across 1 country: China